<DOC>
	<DOC>NCT00399659</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation (OIC) in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis (IA) receive the treatment as follows: Patients on tegaserod 6 mg twice daily (b.i.d.) or 12 mg once daily (o.d.) in the core study will remain on the same dose in the extension (double-blind). Patients on placebo during the core study will receive tegaserod 12 mg o.d. (open-label) Patients who enter this study AFTER the core study interim analysis will receive the selected tegaserod dose regimen (open-label) determined by the core study IA.</brief_summary>
	<brief_title>Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Patient has completed the 12 week double blind treatment of study CHTF919N2201 Planned discontinuation of opioids during the study. Development of any of the medical conditions listed as exclusion criteria for the CHTF919N2201 study. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Opioid, constipation, tegaserod</keyword>
</DOC>